Here, we demonstrate that selecting a combination therapy based on the measurement of ex-vivo killing effect of a 30-drug panel in a 6–9 day-long survival assay resulted in a clinical benefit for a stage IV lung adenocarcinoma patient with multiple EGFR escape mutations and a refractory phenotype for conventional chemotherapy and radiotherapy. This evidence concerns the gene EGFR and lung adenocarcinoma.